(Q37531525)

20 August 2017

Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials) (English)

1 reference

20 August 2017

arterial hypertension

0 references

7

Joseph Loscalzo

1 reference

20 August 2017

Bradley A Maron

1

1 reference

20 August 2017

Aaron B Waxman

2

1 reference

20 August 2017

Alexander R Opotowsky

3

1 reference

20 August 2017

Hunter Gillies

4

1 reference

20 August 2017

Christiana Blair

5

1 reference

20 August 2017

Reza Aghamohammadzadeh

6

1 reference

20 August 2017

Jane A Leopold

8

1 reference

20 August 2017

language of work or name

English

0 references

publication date

7 June 2013

1 reference

American Journal of Cardiology

20 August 2017

1 reference

20 August 2017

112

1 reference

20 August 2017

5

1 reference

20 August 2017

720-725

1 reference

A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906683

Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906683

GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906683

Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906683

Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906683

Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906683

Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906683

Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906683

Aldosterone receptor antagonists: effective but often forgotten

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906683

ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American Coll

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906683

Role of vasopressin and aldosterone in pulmonary arterial hypertension: A pilot study

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906683

Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906683

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906683

Ambrisentan therapy for pulmonary arterial hypertension

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906683

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3906683

Is captopril effective in primary pulmonary hypertension?

2 September 2018

1 reference

12 December 2020

[Activity of renin-angiotensin-aldosterone system (RAAS) and vasopressin level in patients with primary pulmonary hypertension]

1 reference

12 December 2020

Intravenous Epoprostenol in Inoperable Chronic Thromboembolic Pulmonary Hypertension

1 reference

12 December 2020

Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease

1 reference

12 December 2020

Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension

1 reference

12 December 2020

Bosentan therapy for pulmonary arterial hypertension

1 reference

12 December 2020

10.1016/J.AMJCARD.2013.04.051

Identifiers

DOI

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

23751938

1 reference